Shuo Ma

Personal profile

Research Interests

Dr. Ma' clinical and research interests are focused on chronic lymphoid malignancies,including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

Certifications and Licenses

	Medical Oncology
	Hematology
	Internal Medicine

Training Experience

2005	Residency, Resurrection Hospitals
2008	Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

PhD, Northwestern University Feinberg School of Medicine

… → 2000

MD, Beijing Medical University

… → 1994

Research interests

Biologic Therapies
Blood Cancer (leukemia and lymphomas)
Chronic Lymphocytic Leukemia
Hematology
Non-Hodgkin's Lymphoma
Oncology

Fingerprint Dive into the research topics where Shuo Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

11 Similar Profiles

B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences

Therapeutics Medicine & Life Sciences

Dyneins Medicine & Life Sciences

Dictyostelium Medicine & Life Sciences

Waldenstrom Macroglobulinemia Medicine & Life Sciences

Signal Transduction Medicine & Life Sciences

Leukocytes Medicine & Life Sciences

B-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2007 2024

14 Finished
19 Active

Prot #ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Ma, S.

Syneos Health, Inc., Acerta Pharma, LLC

8/21/19 → 8/21/22

Project: Research project

Prot #U2-VEN-109: Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Patients with Relapsed or Refractory CLL/SLL

Ma, S.

TG Therapeutics, Inc.

4/12/19 → 4/12/24

Project: Research project

Prot #BGB-3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

Ma, S.

PRA Health Sciences, BeiGene Ltd.

2/8/19 → 2/8/22

Project: Research project

Prot #BGB-3111-304: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ma, S.

PRA Health Sciences, BeiGene Ltd.

2/5/19 → 2/5/22

Project: Research project

Prot #017004: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Ma, S.

DrugDev Inc., Juno Therapeutics, Inc.

1/18/19 → 1/18/22

Project: Research project

Research Output 1999 2019

2098 Citations
23 Article
7 Review article
2 Chapter
2 Comment/debate
4 More

3 Citations (Scopus)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., Malek, S. & 9 others, Mato, A., Mosse, C., Neppalli, V. T., Shadman, M., Siddiqi, T., Stephens, D., Wagner, N., Dwyer, M. A. & Sundar, H., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 1, p. 12-20 9 p.

Research output: Contribution to journal › Article

B-Cell Chronic Lymphocytic Leukemia

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Lymphoma

Guidelines

1 Citation (Scopus)

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., Hallek, M., Byrd, J. C., Humphrey, K., Zhou, L., Chyla, B., Nielsen, J., Potluri, J., Kim, S. Y., Verdugo, M., Stilgenbauer, S., Wierda, W. G. & Seymour, J. F., Jul 11 2019, In : Blood. 134, 2, p. 111-122 12 p.

Research output: Contribution to journal › Article

B-Cell Chronic Lymphocytic Leukemia

Residual Neoplasm

Chromosomes

Refractory materials

Blood

1 Citation (Scopus)

Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia

Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., Ma, S., Tausch, E., Cramer, P., Huang, J. & 4 others, Mitra, S., Hallek, M., O’Brien, S. M. & Stilgenbauer, S., Jan 1 2019, In : Journal of Clinical Oncology. 37, 16, p. 1391-1402 12 p.

Research output: Contribution to journal › Article

Open Access

B-Cell Chronic Lymphocytic Leukemia

Placebos

Disease-Free Survival

Safety

idelalisib

1 Citation (Scopus)